Understanding the immune response in type 1 diabetes through CD4 T cells from pancreatic islets
The Antigen Repertoire of CD4 T cells from Pancreatic Islets
['FUNDING_R01'] · UNIVERSITY OF COLORADO DENVER · NIH-10873167
This study is looking at how certain immune cells, called CD4 T cells, behave in people with type 1 diabetes to find out what triggers them to attack insulin-producing cells, with the hope of creating better treatments to stop the disease from getting worse.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO DENVER (nih funded) |
| Locations | 1 site (Aurora, UNITED STATES) |
| Trial ID | NIH-10873167 on ClinicalTrials.gov |
What this research studies
This research investigates the role of CD4 T cells in type 1 diabetes (T1D), a condition where the immune system attacks insulin-producing cells in the pancreas. By isolating T cells from the pancreas of individuals with T1D, the study aims to identify specific antigens that these T cells target. This involves analyzing the phenotypes of these T cells to understand their behavior in both healthy and diseased states. The ultimate goal is to develop targeted immunotherapies that can halt the progression of T1D by focusing on the specific antigens involved.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 1 diabetes, particularly those with specific genetic markers associated with the disease.
Not a fit: Patients with type 2 diabetes or other forms of diabetes unrelated to autoimmune mechanisms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new immunotherapies that specifically target the underlying causes of type 1 diabetes, potentially halting or reversing the disease.
How similar studies have performed: Previous research has shown promise in identifying T cell responses in autoimmune diseases, suggesting that this approach could yield valuable insights and therapeutic options.
Where this research is happening
Aurora, UNITED STATES
- UNIVERSITY OF COLORADO DENVER — Aurora, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NAKAYAMA, MAKI — UNIVERSITY OF COLORADO DENVER
- Study coordinator: NAKAYAMA, MAKI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases